MA-WASABI-TECHNOLOGIES
23.1.2024 15:01:31 CET | Business Wire | Press release
Wasabi Technologies, the hot cloud storage company, announces the acquisition of Curio AI from GrayMeta, Inc. Terms of the deal were not disclosed. The acquisition includes both the intellectual property and the visionary team behind Curio, including GrayMeta CEO Aaron Edell, who will join Wasabi as Senior Vice President of AI and Machine Learning. Wasabi will incorporate the Curio AI technology into a new class of AI-powered intelligent storage for the Media and Entertainment industry which it plans to release in Spring 2024.
Curio AI creates a second-by-second index of video stored in Wasabi. “A video archive without detailed metadata is like a library without a card catalog,” said David Friend, Chief Executive Officer, Wasabi Technologies. “This is where AI comes in. AI can find faces, logos, objects, and even specific voices. Without it, finding exactly the segments you are looking for requires tedious and time-consuming manual effort. The acquisition of Curio AI will allow us to revolutionize media storage.”
Video is one of the biggest opportunities in the storage industry. Hundreds of exabytes of video archives exist on aging tape systems, and many more exabytes are generated every year from film, television, sporting events, news, advertising, corporate communications, and countless hours of valuable raw footage and outtakes. Without searchable metadata, it’s extremely time consuming and inefficient to find video segments you need at any given moment.
Curio AI is an intelligent data platform that uses AI to generate rich metadata for media libraries and enables editors and producers to instantly search and retrieve specific media segments based on people, places, events, emotions, logos, landmarks, background audio and more. Curio AI can also detect and transcribe speech in over 50 spoken languages. Customers benefit from more personalized experiences with hyper specific detail, allowing organizations to deliver relevant content to market as fast as possible. Wasabi’s Curio AI-powered storage will provide customers like Liverpool Football Club with the metadata they need to manage troves of digital assets with lightning-fast speed.
“AI-powered storage will allow Wasabi customers to instantly find exactly what they need amongst millions of hours of footage and unleash the value in their archives. We believe this will be the most significant advance in the storage industry since the invention of object storage,” said Edell, Wasabi’s new Senior Vice President of AI and Machine Learning. “I look forward to working with Dave and the exceptional team he has built to write a new future for the media and entertainment industry.”
“Wasabi is on a trajectory that few others in the industry can claim. The advantage of being a hyper-focused company is that we can lead the industry in terms of price, performance, reliability, and innovation. With the acquisition of Curio AI, we are now set to introduce the industry’s first AI-powered intelligent cloud storage,” added Friend. “Like Wasabi’s standard cloud storage, our Curio AI-powered storage will be simple, fast, reliable, and inexpensive. With the acquisition of Curio AI, our customers will not only be able to store data but locate and instantly retrieve exactly what they want.”
About Wasabi Technologies
Wasabi provides simple and affordable hot cloud storage for businesses all over the world. It enables organizations to store and instantly access an unlimited amount of data with no complex tiers or egress or API fees, while delivering predictable costs that save money and industry leading security and performance businesses can count on. Trusted by customers worldwide, Wasabi has been recognized as one of technology’s fastest growing and most visionary companies. Created by Carbonite co-founders and cloud storage pioneers David Friend and Jeff Flowers, Wasabi is a privately held company based in Boston. Wasabi is a Proud Partner of the Boston Red Sox, and the Official Cloud Storage Partner of Liverpool Football Club and the Boston Bruins.
Follow and connect with Wasabi on LinkedIn, X, Facebook, Instagram, and The Bucket.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240123706386/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom